Quarterly report pursuant to Section 13 or 15(d)

Other current assets

v3.23.3
Other current assets
9 Months Ended
Sep. 30, 2023
Other current assets  
Other current assets

Note 8 — Other current assets

Other current assets consisted of the following (in thousands):

September 30, 

December 31, 

    

2023

    

2022

Research and development credits receivable

 

$

40,533

$

30,162

Prepayments

 

11,973

9,472

Clinical materials

 

1,290

1,279

VAT receivable

1,372

490

Other current assets

 

1,683

1,927

$

56,851

$

43,330